GPP
Great Point Partners Portfolio holdings
AUM
$154M
1-Year Return
2.36%
This Quarter Return
+21.91%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$154M
AUM Growth
-$30.2M
(-16%)
Cap. Flow
-$43.8M
Cap. Flow
% of AUM
-28.45%
Top 10 Holdings %
Top 10 Hldgs %
66.56%
Holding
37
New
5
Increased
7
Reduced
9
Closed
10
Top Buys
| 1 |
Ionis Pharmaceuticals
IONS
|
+$9.88M |
| 2 |
Rezolute
RZLT
|
+$9.81M |
| 3 |
Legend Biotech
LEGN
|
+$7.52M |
| 4 |
Akero Therapeutics
AKRO
|
+$5.54M |
| 5 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
+$4.98M |
Top Sells
| 1 |
Akebia Therapeutics
AKBA
|
+$10.9M |
| 2 |
Viridian Therapeutics
VRDN
|
+$10.1M |
| 3 |
Merus
MRUS
|
+$9.98M |
| 4 |
KalVista Pharmaceuticals
KALV
|
+$7.81M |
| 5 |
Ascendis Pharma
ASND
|
+$7.79M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ionis Pharmaceuticals
IONS
$10.2B
| $19.8M | 12.84% |
500,000
+250,000
| +100% | +$9.88M |
|
|
2
Rezolute
RZLT
$705M
| $13.5M | 8.8% |
3,033,462
+2,200,420
| +264% | +$9.81M |
|
3
Amylyx Pharmaceuticals
AMLX
$1.05B
| $12.8M | 8.34% |
2,000,000
+188,004
| +10% | +$1.21M |
|
|
4
Legend Biotech
LEGN
$6.18B
| $12.4M | 8.08% |
350,000
+211,760
| +153% | +$7.52M |
|
|
ABVX
5
Abivax
ABVX
$6.62B
| $9.88M | 6.42% |
1,291,617
-346,494
| -21% | -$2.65M |
|
6
Neurogene
NGNE
$265M
| $7.26M | 4.72% |
485,859
+14,895
| +3% | +$223K |
|
|
7
Akebia Therapeutics
AKBA
$777M
| $7.23M | 4.7% |
1,985,915
-2,987,925
| -60% | -$10.9M |
|
8
Evolus
EOLS
$475M
| $6.63M | 4.31% |
720,118
-224,625
| -24% | -$2.07M |
|
9
Arcellx
ACLX
$4.03B
| $6.59M | 4.28% |
100,000
+55,000
| +122% | +$3.62M |
|
10
Xenon Pharmaceuticals
XENE
$2.86B
| $6.26M | 4.07% |
200,000
-45,272
| -18% | -$1.42M |
|
|
11
Akero Therapeutics
AKRO
$3.46B
| $5.54M | 3.6% |
+103,848
| New | +$5.54M |
|
|
JBIO
12
Jade Biosciences, Inc. Common Stock
JBIO
$247M
| $4.98M | 3.24% |
+498,054
| New | +$4.98M |
|
13
Cytokinetics
CYTK
$6.22B
| $4.96M | 3.22% |
150,000
-220,000
| -59% | -$7.27M |
|
14
Immunovant
IMVT
$2.82B
| $4.19M | 2.73% |
262,176
-112,824
| -30% | -$1.81M |
|
15
Unicycive Therapeutics
UNCY
$75.8M
| $3.8M | 2.47% |
796,558
-301,442
| -27% | -$1.44M |
|
|
16
KalVista Pharmaceuticals
KALV
$775M
| $3.65M | 2.38% |
323,170
-691,197
| -68% | -$7.81M |
|
17
Taysha Gene Therapies
TSHA
$887M
| $3.47M | 2.25% |
+1,500,000
| New | +$3.47M |
|
|
DBVT
18
DBV Technologies
DBVT
$260M
| $3.43M | 2.23% |
+374,679
| New | +$3.43M |
|
19
Zura Bio
ZURA
$134M
| $3.33M | 2.16% |
3,170,194
| – | – |
|
|
UPB
20
Upstream Bio, Inc. Common Stock
UPB
$960M
| $3.29M | 2.14% |
300,000
| – | – |
|
21
Context Therapeutics
CNTX
$76.3M
| $3.07M | 2% |
4,683,711
| – | – |
|
|
CNTA
22
Centessa Pharmaceuticals
CNTA
$3.04B
| $2.96M | 1.92% |
225,000
+75,298
| +50% | +$989K |
|
23
Scholar Rock
SRRK
$3B
| $2.18M | 1.42% |
+61,607
| New | +$2.18M |
|
24
ProMIS Neurosciences
PMN
$20.7M
| $1.28M | 0.83% |
2,645,128
| – | – |
|
25
Pliant Therapeutics
PLRX
$104M
| $986K | 0.64% |
850,000
| – | – |
|